ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- A mixed methods approach (EXPANS) to assess current and future uses of antimicrobials: a case study of ceftaroline.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- The Use of Step-Down Oral Antibiotic Therapy for Uncomplicated Gram-Negative Bacteremia and Risk Factors for Adverse Outcomes.Open forum infectious diseases · 2026Trial
- Pharmacokinetics of Dalbavancin in Complicated Staphylococcus aureus Bacteremia: A Secondary Analysis of the DOTS Randomized Clinical Trial.JAMA network open · 2026Trial
- Safety Monitoring of High-Risk Antibiotics Using Artificial Intelligence: A Narrative Review with Focus on Real-World Evidence.Life (Basel, Switzerland) · 2026Review
- Clinical Outcomes and Safety Profile of Vancomycin in Outpatient Parenteral Antimicrobial Therapy Services: A Systematic Review.Antibiotics (Basel, Switzerland) · 2026Review
- Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With Daptomycin.Open forum infectious diseases · 2026Article
- Challenges and drivers in the implementation of current practices in outpatient parenteral antimicrobial therapy: an international survey.JAC-antimicrobial resistance · 2026Article
- 2026 Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.JAC-antimicrobial resistance · 2026Review
- Emphasizing the O in OPAT: A Pathway for Clinic-Initiated Outpatient Parenteral Antimicrobial Therapy (CI-OPAT) at an Academic Center.Open forum infectious diseases · 2026Article
- Pills and ills: adverse events associated with oral antibiotics for prolonged durations of COpAT treatment courses.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Can implementation of a complex outpatient antimicrobial therapy program reduce readmissions for patients with bone and joint infections?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Oral Therapy for Infective Endocarditis: Where Do We Stand?Pathogens (Basel, Switzerland) · 2025Review
- Post-marketing safety evaluation of Guhong Injection: a multicenter, prospective real-world study of 30,000 cases in China.BMC complementary medicine and therapies · 2025Article
- Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.JAMA · 2025Article
- Delivery of Outpatient Parenteral Antimicrobial Therapy (OPAT) in an Ever-Changing National Health Service (UK): Benefits, Barriers, and Opportunities.Antibiotics (Basel, Switzerland) · 2025Review
- Long-Term Self-Administered Outpatient Parenteral Antimicrobial Therapy in the Treatment of Tuberculosis.Drugs · 2025Observational
- Unmasking the Hidden Hurdles in Outpatient Parenteral Antibiotic Therapy using a lean six-sigma approach.Le infezioni in medicina · 2025Article
- Healthcare utilization and outcomes of patients discharged to skilled nursing facilities on parenteral antimicrobial therapy.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review.The Journal of antimicrobial chemotherapy · 2024Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Background: To better monitor patients on outpatient parenteral antimicrobial therapy (OPAT), we need an improved understanding of risk factors for and timing of OPAT-associated adverse drug events (ADEs). Methods: We analyzed a prospective cohort of patients on OPAT discharged from 2 academic medical centers. Patients underwent chart abstraction and a telephone survey. Multivariable analyses estimated adjusted incident rate ratios (aIRR) between clinical and demographic risk factors and clinician-determined clinically significant ADEs. Descriptive data were used to present patient-reported ADEs. Results: Of 339 patients enrolled in the study, 18.0% experienced an ADE (N = 65), of which 49 were significant (14.5%, 2.24/1000 home-OPAT days). Patients with longer courses of therapy had lower rates of ADEs compared with patients treated for 0-13 days (14-27 days: aIRR, 0.44; 95% confidence interval [CI], 0.20-0.99; at least 28 days: aIRR, 0.11; 95% CI, 0.056-0.21). Risk factors for ADEs included female gender and receipt of daptomycin or vancomycin, while treatment for uncomplicated bacteremia and empiric treatment were associated with lower rates of ADEs. Conclusions: OPAT-related ADEs were common and often occurred within 2 weeks of hospital discharge. Patients on OPAT should be monitored more closely for ADEs, including clinical assessment and laboratory monitoring, especially within the first weeks after hospital discharge and particularly among women and patients who receive vancomycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.